Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2von Hippel-Lindau Disease 1Ulcer 1Smoldering Multiple Myeloma 1Skin Neoplasms 1Sarcoma, Kaposi 1Neoplasms 1Multiple Myeloma 1Melanoma 1Liver Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioma, Capillary 1Hemangioblastoma 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 6cemiplimab 4aldesleukin 3Interleukin-2 3Blood Specimen Collection 3fludarabine 2Specimen Handling 2HhAntag691 2Cyclophosphamide 2Biopsy 2trametinib 1spartalizumab 1sonidegib 1pertuzumab 1lifileucel 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1dabrafenib 1brodalumab 1atezolizumab 1Vitamin A 1Trastuzumab 1Tissue Banks 1Surgical Procedures, Operative 1Standard of Care 1Second Harmonic Generation Microscopy 1Resistance Training 1Red Light 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Skin Neoplasms × Propranolol × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡